BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 29747685)

  • 1. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
    Bajgain P; Tawinwung S; D'Elia L; Sukumaran S; Watanabe N; Hoyos V; Lulla P; Brenner MK; Leen AM; Vera JF
    J Immunother Cancer; 2018 May; 6(1):34. PubMed ID: 29747685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
    Mohammed S; Sukumaran S; Bajgain P; Watanabe N; Heslop HE; Rooney CM; Brenner MK; Fisher WE; Leen AM; Vera JF
    Mol Ther; 2017 Jan; 25(1):249-258. PubMed ID: 28129119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
    Nalawade SA; Shafer P; Bajgain P; McKenna MK; Ali A; Kelly L; Joubert J; Gottschalk S; Watanabe N; Leen A; Parihar R; Vera Valdes JF; Hoyos V
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34815355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
    Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
    J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
    Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
    J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An In Vitro Comparison of Costimulatory Domains in Chimeric Antigen Receptor T Cell for Breast Cancer Treatment.
    Khuisangeam N; Jewmoung S; Thaiwong R; Tudsamran S; Hirankarn N; Suppipat K; Tawinwung S
    J Immunol Res; 2022; 2022():2449373. PubMed ID: 36457849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
    Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
    Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling.
    Wilkie S; van Schalkwyk MC; Hobbs S; Davies DM; van der Stegen SJ; Pereira AC; Burbridge SE; Box C; Eccles SA; Maher J
    J Clin Immunol; 2012 Oct; 32(5):1059-70. PubMed ID: 22526592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy.
    Olguín-Contreras LF; Mendler AN; Popowicz G; Hu B; Noessner E
    Front Immunol; 2021; 12():750478. PubMed ID: 34912334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
    Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
    Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment.
    Sukumaran S; Watanabe N; Bajgain P; Raja K; Mohammed S; Fisher WE; Brenner MK; Leen AM; Vera JF
    Cancer Discov; 2018 Aug; 8(8):972-987. PubMed ID: 29880586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.
    Wilkie S; Picco G; Foster J; Davies DM; Julien S; Cooper L; Arif S; Mather SJ; Taylor-Papadimitriou J; Burchell JM; Maher J
    J Immunol; 2008 Apr; 180(7):4901-9. PubMed ID: 18354214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection.
    Hu W; Huang X; Huang X; Chen W; Hao L; Chen Z
    Biomed Pharmacother; 2019 Oct; 118():109333. PubMed ID: 31545280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.
    Chang ZL; Silver PA; Chen YY
    J Transl Med; 2015 May; 13():161. PubMed ID: 25990251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors.
    Muliaditan T; Halim L; Whilding LM; Draper B; Achkova DY; Kausar F; Glover M; Bechman N; Arulappu A; Sanchez J; Flaherty KR; Obajdin J; Grigoriadis K; Antoine P; Larcombe-Young D; Hull CM; Buus R; Gordon P; Grigoriadis A; Davies DM; Schurich A; Maher J
    Cell Rep Med; 2021 Dec; 2(12):100457. PubMed ID: 35028604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells.
    Munisvaradass R; Kumar S; Govindasamy C; Alnumair KS; Mok PL
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.